Lyra Therapeutics (LYRA) Q2 2025 earnings summary

Executive summary

• Positive ENLIGHTEN 2 Phase 3 results for LYR-210 in CRS patients, meeting primary and key secondary endpoints; ENLIGHTEN 1 previously failed, prompting major restructuring and a 75% workforce reduction.

• June 2025 financing extended cash runway into Q3 2026, supporting ongoing development and operations.

• Company reengaged with FDA, preparing for a Type C meeting to align on NDA submission for LYR-210.

• Collaboration with LianBio faces uncertainty due to LianBio's wind-down; company evaluating strategic options and subleasing efforts for costly leaseholds.

Financial highlights

• Net loss for Q2 2025 was $7.4M, down from $48.1M in Q2 2024; net loss for six months ended June 30, 2025 was $16.0M, down from $70.6M year-over-year.

• Operating expenses for Q2 2025 were $9.0M, reflecting lower R&D and G&A costs after restructuring.

• Cash and cash equivalents as of June 30, 2025 were $29.8M, compared to $40.6M at year-end 2024.

• No impairment costs in Q2 2025 versus $24.7M in Q2 2024.

• June 2025 financing raised $5.0M gross ($4.3M net) via direct offering and private placement warrants.

Outlook and guidance

• Cash runway expected to fund operations into Q3 2026, but substantial doubt remains about ability to continue as a going concern without additional funding.

• Company plans to seek FDA feedback on ENLIGHTEN data to determine regulatory path for LYR-210; manufacturing for LYR-210 restarted in early 2025 for potential further trials.

• Upcoming Type C FDA meeting in H2 2025 to discuss NDA submission for LYR-210.

• No expectation of product sales revenue in the near term; future revenue primarily dependent on LianBio collaboration, which is at risk.